Groupe Hospitalier de la Rochelle Ré Aunis
La Rochelle, France
Location status: Recruiting
NCT Number: NCT06742671
Giant cell arteritis is a vasculitis, i.e. inflammation of the artery walls, which generally affects people over the age of 50. Diagnosis can be long and difficult, as the clinical signs are not specific (headache, pain in the jaw, scalp, shoulders and/or pelvis, abdominal pain, weight loss, etc.), but it must be made quickly, given the risk of complications.
The reference method for diagnosis was initially based on clinical suspicion and analysis of a "piece of temporal artery" (biopsy) performed in the operating theatre under local anaesthetic. Since the mid-1990s, improvements in ultrasound techniques have made it possible to identify a sign, known as a halo, on the temporal arteries that is typical of patients with Giant Cell Arteritis. A prospective multicenter study published in 2024 demonstrated that, in patients with a clinical suspicion of Giant Cell Arteritis, if a halo was found on both temporal arteries by ultrasound, there was no need for a biopsy. This study is at the origin of a change in practices in the diagnosis and care of patients suffering from this disabling disease.
To facilitate early diagnosis, a fast-track pathway has been set up. The aim is to make a rapid diagnosis, thereby reducing the risk of after-effects, shortening the length of hospital stays, considering outpatient treatment and limiting the number of biopsies.
The investigators propose to evaluate the performance of this fast-track pathway.
Interested in participating?
Request Info50 year and older
All sexes
Observational
La Rochelle, France
Location status: Recruiting
Giant Cell Arteritis (GCA) or temporal arteritis is a systemic vasculitis (inflammation of the artery walls) that generally affects people over 50 years old, with a peak frequency between 70 and 80 years. The diagnosis is sometimes long and difficult to make due to non-specific clinical signs but must be rapid because of the risk of arterial occlusion that can lead to vision loss or stroke.
Two GCA presentations can be detected :
The reference method for diagnosis has been based on clinical presumption. The presence of an inflammatory syndrome in biology and the analysis of a temporal artery biopsy.
Since the mid-1990s, the improvement of ultrasound techniques, particularly with the appearance of high frequency probes, made it possible to detect inflammation of the temporal arteries in some cases. Each center published retrospective studies with the aim of avoiding biopsy but without really allowing the modification of clinical practices.
A prospective multicenter study (doi: 10.7326/M23-3417) published in 2024 proved that in patients with high clinical probability of GCA, in case of bilateral positivity on temporal artery ultrasound (hypoechoic halo) it was not necessary to resort to a biopsy.
When the ultrasound of bilateral arteries (particularly temporal and axillary) showed an abnormality such as a halo (inflammation), the diagnosis was made and did not require a biopsy.
When the ultrasound was negative (or only present on one artery or another arterial axis), biopsy was necessary. In 50% of cases, the biopsy result was negative. Among these negative cases, a certain number were nevertheless retained as Giant Cell Arteritis, according to the clinician's assessment, and others were subjected to differential diagnoses.
While with a biopsy the time to perform the procedure and obtain its interpretation was 10 days, ultrasound only requires one day to make a diagnosis.
This study is at the origin of a change in diagnosing and treating patients with this Giant Cell Arteritis.
In order to facilitate early diagnosis, a fast-track pathway has been set up based on the model published in 2024 (doi: 10.26635/6965.6376).
The investigators propose to evaluate the performance of this fast-track clinic.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From initial GCA suspicion by the clinician to the ultrasound result (up to day 7)
Number of patients for whom the delay between GCA suspicion and ultrasound result is less than 7 days
Time frame: From initial GCA suspicion by the clinician to corticosteroid prescription (up to 1 month)
The duration between suspicion of GCA and corticosteroid prescription
Time frame: From clinical suspicion to the final diagnosis (around 1 month)
Number of patients with an alternative diagnosis
Time frame: From clinical suspicion to pathology results (up to 15 days)
The number of ultrasound negative patients with a positive result according to pathology analysis of temporal artery biopsy
Time frame: From clinical suspicion to final diagnosis (around 1 month)
Number of patients for whom Doppler ultrasound and biopsy analysis results are negative but who are considered to have GCA by the clinician
Contact information is provided by the study sponsor or research team.
Caroline Allix-Béguec, Ph.D.
CONTACT
Cécile Duchiron, Ph.D.
CONTACT
Groupe Hospitalier de la Rochelle Ré Aunis
Other
Acronym: QuickDx-GCA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07108387
Arteritis, Autoimmune Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07060274
Arteritis, Autoimmune Diseases
Le Mans, Sarthe, France
View Trial DetailsNCT07552636
Arteritis, Autoimmune Diseases
Aalborg, Denmark
View Trial DetailsNCT07206238
Arteritis, Autoimmune Diseases
Glostrup Municipality, Denmark
View Trial Details